How to appeal an Independence Blue Cross thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Independence Blue Cross-specific note: BCBS licensee covering 5-county SE Pennsylvania (Philadelphia, Bucks, Chester, Delaware, Montgomery). Parent of AmeriHealth (NJ/DE). FutureScripts is the in-house PBM. PA Insurance Department oversees fully-insured complaints.

What Independence Blue Cross's policy requires for thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy

Cited policy: Anthem / BCBSA Evidence Positioning System: Teprotumumab for Thyroid Eye Disease

EUGOGO moderate-to-severe TED; CAS-based activity threshold; quantitative proptosis measurement; prior systemic glucocorticoid trial or documented contraindication; euthyroid status; safety baselines (audiogram, glucose / A1c); excludes pregnancy.

How Independence Blue Cross denies thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy — and how to counter it

Where Independence Blue Cross pushes back: 1) Documentation insufficient on CAS / proptosis; 2) Mild TED — selenium recommended first; 3) Steroid trial inadequate; 4) Plan exclusion of specialty biologics.

Counter-arguments that hold up: Submit complete CAS 7-item itemized score and Hertel measurements with base reading. For mild TED selenium is first-line per EUGOGO (Marcocci NEJM 2011) — only escalate to Tepezza for moderate-to-severe. Document failed methylpred or contraindication. For 'plan exclusion' confirm administration under medical (not pharmacy) benefit using HCPCS J3241; reroute. Cite OPTIC + AAO PPP 2022.

What Independence Blue Cross typically denies for thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy

Across Independence Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy, expect:

• Out-of-network for SE Pennsylvania providers
• AmeriHealth-administered plan denials
• Specialty drug PA via FutureScripts (PBM)
• Behavioral health network adequacy

Treatments most often denied in this category

These are the thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Tepezza standard course
• Tepezza re-treatment
• Tepezza chronic-stable
• IV methylprednisolone
• Oral prednisone
• Orbital radiotherapy

How to submit the appeal to Independence Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Independence Blue Cross cited in the denial.
3. File the appeal through Independence Blue Cross's portal (members: https://www.ibx.com ; providers: https://www.ibxpress.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Independence Blue Cross's prior-authorization criteria by drug: Independence Blue Cross PA criteria on ApprovalHelp.